Markers of inflammation: data from the MOSAIC randomised trial of CPAP for minimally symptomatic OSA.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 25182045.
- Also identified by DOI 10.1136/thoraxjnl-2014-205958.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Multi-centre Obstructive Sleep Apnoea Interventional Cardiovascular (MOSAIC) trial compared 6 months of CPAP therapy, versus no CPAP, in 391 patients with minimally symptomatic obstructive sleep apnoea (OSA). We now report some exploratory outcomes, markers of systemic inflammation (interleukin 6 (IL-6), IL-10, C reactive protein, tumour necrosis factor). We found no consistent changes (all p values >0.13). ISRCTN 34164388.
Medical subject headings
- C-Reactive Protein
- Inflammation
- Interleukin-10
- Interleukin-6
- Sleep Apnea, Obstructive
- Tumor Necrosis Factor-alpha